Brokerages Set Liquidia Co. (NASDAQ:LQDA) Target Price at $26.63

Liquidia Co. (NASDAQ:LQDA) has been assigned a consensus rating of “Buy” from the nine brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $26.63.

Several equities research analysts recently issued reports on LQDA shares. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Liquidia in a report on Thursday, March 20th. Scotiabank reiterated an “outperform” rating on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC raised their price target on shares of Liquidia from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. Finally, Wells Fargo & Company initiated coverage on shares of Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price objective for the company.

Insider Buying and Selling at Liquidia

In other news, CFO Michael Kaseta sold 23,370 shares of Liquidia stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $275,298.60. Following the completion of the transaction, the chief financial officer now directly owns 401,755 shares in the company, valued at approximately $4,732,673.90. The trade was a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Roger Jeffs sold 22,343 shares of the stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $263,200.54. Following the completion of the sale, the chief executive officer now directly owns 1,019,177 shares in the company, valued at approximately $12,005,905.06. The trade was a 2.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,245 shares of company stock valued at $843,326. Company insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its position in shares of Liquidia by 735.1% in the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock worth $1,402,000 after purchasing an additional 123,402 shares during the last quarter. Barclays PLC grew its stake in Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock worth $999,000 after buying an additional 72,591 shares in the last quarter. Whitefort Capital Management LP increased its holdings in shares of Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after buying an additional 927,546 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Liquidia by 855.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock valued at $2,354,000 after buying an additional 210,753 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Liquidia by 144.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after acquiring an additional 230,820 shares during the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Trading Down 2.3 %

LQDA opened at $14.75 on Thursday. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -9.05 and a beta of 0.07. The company’s fifty day moving average price is $15.14 and its two-hundred day moving average price is $12.47. Liquidia has a 1-year low of $8.26 and a 1-year high of $16.81.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The business had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, equities analysts forecast that Liquidia will post -1.51 earnings per share for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).